Artificial intelligence is rapidly reshaping clinical research, but one of the greatest opportunities lies in medical imaging. Every year, clinical trials generate enormous volumes of imaging data that require expert analysis to determine whether new treatments are working. Traditional image review can be time consuming, expensive, and subject to variability, slowing the development of life changing medicines. As pharmaceutical companies seek faster and more accurate ways to evaluate therapies, advanced imaging analytics are becoming a critical component of modern drug development. UK based health technology company Qureight is addressing this challenge with an enterprise grade imaging platform powered by artificial intelligence, and the company has now secured fresh funding to expand its technology into new disease areas.
Qureight has raised $20 million in a Series B financing round led by Molten Ventures, with participation from existing investors including Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
The latest investment brings the company’s total funding to more than €27 million and will accelerate the expansion of its AI driven imaging platform while supporting the launch of new products across additional therapeutic areas.
Advancing AI Driven Clinical Imaging
Qureight develops an end to end imaging platform that supports pharmaceutical companies running clinical trials for lung and heart diseases.
The company combines enterprise grade imaging services, artificial intelligence, and advanced data science to improve how medical images are collected, analysed, and interpreted throughout the clinical development process.
Its platform enables biopharmaceutical companies to generate more accurate clinical endpoints, improve patient selection, and accelerate decision making during trials.
By integrating imaging expertise with AI powered analytics, Qureight aims to reduce trial complexity while improving the quality of clinical evidence.
Building an AI Imaging Laboratory
A central focus of the new funding is the expansion of Qureight’s AI imaging laboratory.
The facility will house the company’s three dimensional chest imaging foundation model, which has been developed to significantly reduce both the amount of data and the time required to create new disease specific AI models.
Rather than building every model from the beginning, researchers can use this foundation technology to accelerate development across multiple medical conditions.
The company believes this approach will enable faster innovation while supporting a broader range of clinical research programmes.
Supporting Smarter Clinical Trials
Qureight’s platform combines several integrated capabilities designed specifically for modern clinical trials.
Its global imaging services help pharmaceutical companies manage imaging data efficiently while supporting faster site onboarding and patient enrolment across international studies.
The platform also includes proprietary AI powered lung imaging biomarkers capable of measuring structural changes associated with disease progression.
In addition, advanced data science tools such as synthetic control arms allow researchers to compare trial participants with carefully constructed reference populations, helping reduce study costs and shorten development timelines.
Together, these technologies provide pharmaceutical companies with more precise and efficient methods for evaluating new therapies.
Expanding Into New Disease Areas
The latest investment will support expansion beyond the company’s established expertise in lung fibrosis.
Qureight plans to introduce new AI imaging models covering asthma, pulmonary hypertension, bronchiectasis, and drug induced lung toxicity, areas where demand for advanced imaging analytics continues to grow.
These additions will strengthen the company’s disease agnostic clinical trials platform while expanding opportunities across respiratory and cardiovascular medicine.
The business is already working with multiple biopharmaceutical partners, providing real time imaging insights that support ongoing clinical research programmes.
Accelerating Medical Innovation
As precision medicine becomes increasingly important, medical imaging is evolving into a critical source of clinical intelligence for drug development.
Qureight believes artificial intelligence can significantly improve the speed, accuracy, and efficiency of imaging based clinical research while enabling pharmaceutical companies to bring innovative therapies to patients more quickly.
With fresh funding, an expanding AI imaging laboratory, and a growing portfolio of disease models, the company is positioning itself as a leader in enterprise imaging for clinical trials. By combining advanced artificial intelligence, medical imaging expertise, and data science within a unified platform, Qureight aims to accelerate the next generation of clinical research across respiratory, cardiovascular, and other complex diseases.
